Darovasertib
Phase 2Active 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uveal Melanoma
Conditions
Uveal Melanoma
Trial Timeline
Jul 3, 2023 → Apr 30, 2030
NCT ID
NCT05907954About Darovasertib
Darovasertib is a phase 2 stage product being developed by IDEAYA Biosciences for Uveal Melanoma. The current trial status is active. This product is registered under clinical trial identifier NCT05907954. Target conditions include Uveal Melanoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07015190 | Phase 3 | Recruiting |
| NCT05907954 | Phase 2 | Active |
Competing Products
20 competing products in Uveal Melanoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 52 |
| Selumetinib, 100mg + Selumetinib, 125mg + Selumetinib, 150mg + Selumetinib, 175mg + Selumetinib, 200mg + Selumetinib, 225mg | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab + Entinostat | Merck | Phase 2 | 52 |
| Pembrolizumab + Olaparib | Merck | Phase 2 | 52 |
| Pembrolizumab 25 MG/1 ML Intravenous Solution | Merck | Phase 2 | 52 |
| AEB071 | Novartis | Phase 1 | 33 |
| LXS196 + LXS196 and HDM201 | Novartis | Phase 1 | 33 |
| DYP688 | Novartis | Phase 1/2 | 41 |
| RAD001 (Everolimus) and Pasireotide (SOM230) LAR | Novartis | Phase 2 | 52 |
| ranibizumab + triamcinolone acetonide | Novartis | Phase 2/3 | 65 |
| Crizotinib | Pfizer | Phase 2 | 51 |
| Dacarbazine + Sunitinib | Pfizer | Phase 2 | 51 |
| AEB071 + MEK162 | Pfizer | Phase 1/2 | 40 |
| Binimetinib + Belinostat | Pfizer | Phase 2 | 51 |
| Ipilimumab + Nivolumab | Bristol Myers Squibb | Phase 1 | 32 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 51 |
| ipilimumab + Nivolumab | Bristol Myers Squibb | Phase 2 | 51 |
| ZIV-Aflibercept + Cemiplimab | Sanofi | Phase 2 | 51 |
| Ziv-Aflibercept | Regeneron Pharmaceuticals | Phase 2 | 51 |
| XmAb®23104 + Yervoy® (ipilimumab) | ICON plc. | Phase 1 | 30 |